Ipamorelin + HGH Fragment 176-191

A fat-loss-oriented pairing: ipamorelin raises the body's own GH pulse, while HGH Fragment 176-191 supplies the lipolytic tail of the GH molecule directly to fat tissue without raising IGF-1 or blood glucose. The logic is to hit fat mobilization from two directions — pituitary signaling and direct fat-cell action — with a side-effect profile that stays mild.

Components & typical mixing

How the protocol is typically run

• →HGH Fragment 176-191: 250–500 mcg per injection, most commonly 250 mcg twice daily — one dose fasted on waking, one before bed or pre-workout.
• →Ipamorelin: 200–300 mcg, 1–2× daily, with the before-bed dose considered the non-negotiable one (it rides the natural nighttime GH pulse). Many run it with CJC-1295 no DAC as well.
• →Timing rule: keep the fasted morning Frag dose at least 30–60 minutes away from carbohydrates — its fat-mobilizing effect is blunted by an insulin spike.
• →Cycle: 8–12 weeks is the common window; results are gradual and depend on a calorie deficit — the stack accelerates, it does not replace.
• →Same syringe: both are subcutaneous and can be drawn together for the evening dose if reconstituted separately first.

Cautions

Neither compound is approved; HGH Frag's human trial data are thin and ipamorelin's long-term data limited. The most common failure mode is expecting the stack to work without a deficit. Both are prohibited in tested sport.

Other stacks

Educational reference describing commonly published protocols — not medical advice. Most compounds referenced are research chemicals without approval for human use.